PPTA Twitter

PlasmaProteins
PlasmaProteins Johan Prevot, Executive Director of @ipopi_info , is a leading global voice for patient access to #PPTs . @PlasmaProteins is proud to work with him and his partner organizations to ensure those who need these therapies can receive them. Read more: bit.ly/30xcxQz pic.twitter.com/BOF4y5uVTj
2 days ago.
PlasmaProteins
PlasmaProteins . @PlasmaProteins & @HIYDglobal every patient’s story helps us #AdvocateForPPTs . Tell us your story at share.howisyourday.org pic.twitter.com/jVmgvMKHtE
7 days ago.

New Supplement Addresses Hemolytic Complications of IVIG Infusions

A special supplement to the July issue of Transfusion, consisting of 19 referred papers, focuses on the frequency and pathogenesis of and strategies to mitigate intravenous immunoglobulin-mediated hemolysis.

Transfusion cover

In January 2014, PPTA, along with the Food and Drug Administration and the National Heart, Lung and Blood Institute, jointly hosted a workshop entitled, “Strategies to Address Hemolytic Complications of Immune Globulin Infusions.” The workshop examined strategies to reduce the occurrence and severity of hemolysis, including: patient risk factors, the potential of in vitro testing, and the link between hemolytic events and new indications for IG products. All of the strategies covered in the workshop are spotlighted in the new supplement.

George Schreiber, Sc.D., Director, PPTA Epidemiology, and Harvey Klein, M.D., Chief, Department of Transfusion Medicine, Clinical Center, NIH, served as guest editors of the supplement.


Transfusion is free to AABB members. Nonmembers may subscribe through Wiley-Blackwell or by calling +1.800.835.6770.

 

Copyright © 2020 PPTA. All rights reserved. (202) 789-3100